Summary: Researchers have identified a critical cellular switch that helps determine whether Alzheimer’s disease pathology leads to clinical dementia. By analyzing brain tissue from older adults—including cognitively healthy centenarians—the team mapped how microglia, the brain’s resident immune cells, change states in response to amyloid-beta and tau. Their results point to active, age-dependent cellular mechanisms of resilience that can uncouple hallmark protein accumulation from neurodegeneration, revealing promising therapeutic targets to prevent cognitive decline.

The study shows that cognitive resilience is not simply a lack of pathology but an active cellular response. Distinct microglial programs either prevent inflammatory states from progressing into neurodegenerative programs or decouple later microglial activity from destructive tau pathology. These findings highlight high-priority intervention points to stop disease progression before a decisive “tipping point” toward dementia.

Key Facts

• The pathology paradox: Alzheimer’s disease affects more than 55 million people worldwide, yet classic hallmarks—amyloid-beta plaques and tau tangles—do not always produce dementia. Some people remain cognitively intact despite heavy biomarker loads, suggesting active cellular resilience mechanisms.
• Six spatial tissue domains: Using high-resolution spatial transcriptomics and single-nucleus sequencing on human donor material, researchers defined six distinct tissue domains that reflect spatial and temporal stages of Alzheimer’s progression.
• Microglial state transition: A key shift was identified in microglial programming:
  • Early stage: Microglia adopt a localized inflammatory profile associated with amyloid-beta plaques.
  • Late stage: Microglia switch to an antigen-presenting state that appears with tau pathology and neurodegeneration.
• Two routes to resilience: The brain can resist clinical decline through two distinct, age-dependent pathways:
  • Octogenarian track: People in their 80s who remain cognitively intact show the early microglial inflammatory response but block the transition to the later degenerative immune state.
  • Centenarian track: Cognitively healthy centenarians activate the late-stage microglial program, but it is uncoupled from tau accumulation and harmful neurodegeneration.
• Therapeutic implications: Targeting microglial state transitions—particularly pathways like TREM2—may preserve beneficial early responses and prevent immune-driven progression toward tau pathology and cognitive decline.

Source: VIB

Researchers from VIB, KU Leuven, the UK-DRI and Muna Therapeutics studied brain tissue from older adults with and without cognitive decline, including cognitively healthy centenarians, to identify cellular programs and immune-cell states linked to disease progression and resilience.

Their findings, published in Nature Medicine, point to microglial state changes as a critical interface in Alzheimer’s disease and as a promising target for therapies designed to preserve cognition.

“This has been an exciting journey with many partners. The study, entirely based on human donor material, provides insight into one type of resilience mechanism in the progression of AD to dementia,” says Prof. Bart De Strooper (VIB-KU Leuven Center for Neuroscience, KU Leuven), ERC grantee and co-senior author of the study.

Alzheimer’s disease is marked by accumulation of amyloid-beta plaques and tau tangles, but the link between these hallmarks and dementia is complex. Increasing evidence indicates that the brain’s response—particularly the behavior of microglia—shapes whether pathology progresses to cognitive decline or remains clinically silent.

Microglia change dramatically over the course of disease. By characterizing these shifts at single-cell and spatial resolution, the research team uncovered divergent microglial programs that correlate with either progression to dementia or resilience despite heavy pathology.

“Understanding better how the brain resists the disease will provide new avenues towards therapies to prevent neurodegeneration and dementia,” adds Prof. Mark Fiers (VIB-KU Leuven), co-senior author of the study.

Mapping a Critical Transition in Alzheimer’s Disease

To explore resilience mechanisms, the team combined spatial transcriptomics and single-nucleus RNA sequencing of superior frontal cortex samples from octogenarians with and without dementia and from cognitively intact centenarians with comparable amyloid-beta accumulation. They identified six tissue domains forming a spatial continuum of Alzheimer’s pathology. A pivotal inflection point separates domains dominated by amyloid-linked inflammatory signals from those associated with tau pathology and neurodegeneration.

This inflection correlates with a pronounced microglial state change: early inflammatory programs tied to plaques give way to late antigen-presenting programs that emerge alongside tau. The timing and coupling of this transition appear to determine whether pathology advances to clinical dementia.

Two Different Routes to Resilience

The study highlights two distinct resilience patterns. Resilient octogenarians exhibited early plaque-associated microglial activation but lacked the late-stage antigen-presenting program linked to progression. In contrast, centenarians displayed the late microglial program, yet it was uncoupled from harmful tau accumulation and neurodegeneration.

These patterns suggest resilience results from how the brain modulates immune responses to pathology—either by preventing a harmful state transition or by disconnecting that state from downstream neurodegeneration. Interventions that stabilize beneficial early microglial responses or block the shift to degenerative programs could be most effective if applied before the critical tipping point is reached.

“These findings open new opportunities to target microglial states—especially pathways such as TREM2—and extend resilience rather than simply focusing on plaque removal. We are excited to continue this journey and understand the causal role of microglial transitions leading to the identification of novel therapeutic approaches to delay or prevent disease progression,” concludes Niels Plath, CSO of Muna Therapeutics.

Key Questions Answered

Editorial Notes

• This article was edited by a Neuroscience News editor.
• Journal paper reviewed in full.
• Additional context added by staff.

About this Alzheimer’s disease research news

Author: Gunnar De Winter
Source: VIB
Contact: Gunnar De Winter – VIB
Image: The image is credited to Neuroscience News

Original Research: Open access. “Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience” by Ashley Lu et al., published in Nature Medicine. DOI: 10.1038/s41591-026-04393-8

---

Abstract

Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience

Alzheimer’s disease is shaped by how brain cells respond to amyloid-β (Aβ) and tau rather than being an inevitable outcome of protein accumulation. Combining spatial transcriptomics and single-nucleus RNA sequencing of superior frontal cortex from octogenarians with and without dementia and from cognitively intact centenarians, the study identified six tissue domains representing a spatial pathological continuum. A key inflection point marks a shift from Aβ-associated inflammatory changes to tau-associated cellular programs. This transition coincided with a microglial switch from early inflammatory to late antigen-presenting phenotypes (early and late plaque-induced gene programs). Resilient individuals showed divergent patterns: octogenarians without dementia lacked late PIG activation, while centenarians exhibited late PIG activity uncoupled from tau accumulation. These findings position microglial state transitions at the Aβ–tau interface as candidate points of resilience with therapeutic relevance.